111 related articles for article (PubMed ID: 24461951)
1. Outcomes in patients with recurrent/progressive glioblastoma treated with bevacizumab funded by a regional cancer drug fund.
Dixit S; Hatfield P; Clenton S; Loughrey C; Hingorani M
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):238-9. PubMed ID: 24461951
[No Abstract] [Full Text] [Related]
2. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
3. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
[No Abstract] [Full Text] [Related]
4. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
Desjardins A
Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258
[No Abstract] [Full Text] [Related]
5. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
6. Should the cost of care for patients with glioblastoma influence treatment decisions?
Dropcho EJ
Continuum (Minneap Minn); 2012 Apr; 18(2):416-20. PubMed ID: 22810136
[TBL] [Abstract][Full Text] [Related]
7. Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.
Hoskins PJ; Fung-Kee-Fung M; Miller D; Gotlieb W
J Clin Oncol; 2015 May; 33(14):1539-42. PubMed ID: 25847922
[No Abstract] [Full Text] [Related]
8. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
9. Watchdog set to reject four drugs for kidney cancer on the NHS.
O'Dowd A
BMJ; 2008 Aug; 337():a1262. PubMed ID: 18703648
[No Abstract] [Full Text] [Related]
10. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
Nowosielski M; Wiestler B; Goebel G; Hutterer M; Schlemmer HP; Stockhammer G; Wick W; Bendszus M; Radbruch A
Neurology; 2014 May; 82(19):1684-92. PubMed ID: 24727314
[TBL] [Abstract][Full Text] [Related]
11. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
12. Bevacizumab as first-line therapy for glioblastoma.
Piccioni D; Lai A; Nghiemphu P; Cloughesy T
Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
[TBL] [Abstract][Full Text] [Related]
13. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
14. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for glioblastoma: what can we learn from patterns of progression?
Wen PY; Junck L
Neurology; 2014 May; 82(19):1670-1. PubMed ID: 24727316
[No Abstract] [Full Text] [Related]
16. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine and cost-based decision making.
The Lancet
Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
[No Abstract] [Full Text] [Related]
18. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
Hawkes N
BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
[No Abstract] [Full Text] [Related]
19. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
20. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]